GlioGuard Therapeutic & Diagnostic System
Glioblastoma (GBM)
Pre-clinicalActive
Key Facts
About GlioGuard
GlioGuard is a private, preclinical-stage biotech targeting glioblastoma, one of the most aggressive and lethal cancers with a dire unmet need. The company has developed a two-pronged strategy: a proprietary formulation of repurposed drugs claimed to be effective in 40% of GBM cases, and a companion diagnostic to identify likely responders for targeted therapy. Founded by seasoned neuroscientists and operating from Trieste and Milan, Italy, the company is built on strong academic research and an international patent, but remains pre-revenue and faces significant development and commercialization risks inherent to oncology drug development.
View full company profileTherapeutic Areas
Other Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| DOC1021 | Diakonos Oncology | Phase 2 |
| Lead CAR-T Program | Kiragen Bio | Pre-clinical |
| GBM Immunotherapy (with SandboxAQ) | iOncologi | Pre-clinical |
| DCVax®-L | Northwest Biotherapeutics | Phase 3 |
| Lucicebtide (ST101) | Sapience Therapeutics | Phase 2 |
| Glioblastoma Assay Optimization (CPRIT Grant) | SingleCell Biotechnology | Pre-clinical |
| Lead Program (unspecified) | BlueHaven Therapeutics | Preclinical |
| TLX101 (Pixclara® / 131I-IPA) | Telix Pharmaceuticals | Phase 3 |
| Paxalisib | Kazia Therapeutics | Phase II/III |